Which peptides are studied for heart and blood vessel conditions?
Short answer
8 profiles here are grouped under “Heart and blood vessels”: 6 FDA-approved, 1 in clinical trials and 1 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 6
FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.4,5
Is dulaglutide FDA-approved? · Dulaglutide vs Semaglutide · Dulaglutide vs Tirzepatide
FDA-approved as Ozempic, Rybelsus and Wegovy8,9,10,11
FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.8,9,10,11
Is semaglutide FDA-approved? · Semaglutide vs Tirzepatide · Semaglutide vs Retatrutide
FDA-approved as Vasostrict for vasodilatory shock12,13
FDA-approved. Drugs@FDA lists Vasostrict with an original approval date of April 17, 2014. The cited label has no boxed warning.12,13
Is vasopressin FDA-approved? · Oxytocin vs Vasopressin · Desmopressin vs Vasopressin
In clinical trials 1
In clinical trials; not FDA-approved14,15,16
Not FDA-approved. No FDA approval is reported in the sources reviewed here, and a phase 3 trial in type 2 diabetes is registered as recruiting.14,15
Is efpeglenatide FDA-approved? · Efpeglenatide vs Semaglutide
Not FDA-approved 1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2Bivalirudin for injection, powder, lyophilized, for solution (Sandoz Inc.) · SPL version 5 · published 2026-07-29 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 3Drugs@FDA: ANGIOMAX (bivalirudin), NDA 020873 · original approval December 15, 2000 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 4TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 5Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Eptifibatide injection (Baxter Healthcare Company) · SPL version 13 · published 2026-05-21 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 7Drugs@FDA: INTEGRILIN (eptifibatide), NDA 020718 · original approval May 18, 1998 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 8WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 9Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 10Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 11Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 12VASOSTRICT (vasopressin) injection · SPL version 49 · published 2026-05-18 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 13Drugs@FDA: VASOSTRICT (vasopressin), NDA 204485 · original approval April 17, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 14Efpeglenatide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 15ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 16Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 17Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications (May 14, 2020) · FR Doc. 2020-10367 ↗
Federal Register · Official source · Source checked November 15, 2026
- 18Drugs@FDA: NATRECOR (nesiritide), NDA 020920 · original approval August 10, 2001 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026